Abouzayed, A.; Tano, H.; Nagy, Á.; Rinne, S.S.; Wadeea, F.; Kumar, S.; Westerlund, K.; Tolmachev, V.; Eriksson Karlström, A.; Orlova, A.
Preclinical Evaluation of the GRPR-Targeting Antagonist RM26 Conjugated to the Albumin-Binding Domain for GRPR-Targeting Therapy of Cancer. Pharmaceutics 2020, 12, 977.
https://doi.org/10.3390/pharmaceutics12100977
AMA Style
Abouzayed A, Tano H, Nagy Á, Rinne SS, Wadeea F, Kumar S, Westerlund K, Tolmachev V, Eriksson Karlström A, Orlova A.
Preclinical Evaluation of the GRPR-Targeting Antagonist RM26 Conjugated to the Albumin-Binding Domain for GRPR-Targeting Therapy of Cancer. Pharmaceutics. 2020; 12(10):977.
https://doi.org/10.3390/pharmaceutics12100977
Chicago/Turabian Style
Abouzayed, Ayman, Hanna Tano, Ábel Nagy, Sara S. Rinne, Fadya Wadeea, Sharmishtaa Kumar, Kristina Westerlund, Vladimir Tolmachev, Amelie Eriksson Karlström, and Anna Orlova.
2020. "Preclinical Evaluation of the GRPR-Targeting Antagonist RM26 Conjugated to the Albumin-Binding Domain for GRPR-Targeting Therapy of Cancer" Pharmaceutics 12, no. 10: 977.
https://doi.org/10.3390/pharmaceutics12100977
APA Style
Abouzayed, A., Tano, H., Nagy, Á., Rinne, S. S., Wadeea, F., Kumar, S., Westerlund, K., Tolmachev, V., Eriksson Karlström, A., & Orlova, A.
(2020). Preclinical Evaluation of the GRPR-Targeting Antagonist RM26 Conjugated to the Albumin-Binding Domain for GRPR-Targeting Therapy of Cancer. Pharmaceutics, 12(10), 977.
https://doi.org/10.3390/pharmaceutics12100977